Abstract
PPAR-γ has been known to induce suppression, differentiation and reversal of malignant changes in colon cancer in vitro. However, there are several reports that PPAR-γ ligands enhance colon polyp development in APCmin mice in vivo. These contradictory results have not yet been thoroughly explained. To explain the contradictory results, we analyzed the effects of different concentrations of the PPAR-γ agonist, 15-deoxy-D12, 14-prostaglandin (15-d Δ PGJ2) and pioglitazone, on APC gene-mutated colon cancer cell lines (HT-29). We measured cell growth and suppression by cell count and MTT assay and analyzed the expression of β-catenin and c-Myc protein by Western blot. In addition, we inoculated HT-29 cells into APC min mice to compare tumor size. High concentrations (10-100 μM/L 15-d Δ PGJ2 and pioglitazone) of PPAR-γ ligand suppressed growth, while low concentrations (0.01-1 μM/L 15-d Δ PGJ2 and pioglitazone) of PPAR-γ ligand promoted growth. In particular, the effects of 0.1 μM/L 15-d Δ PGJ2 and pioglitazone on cell growth were statistically significant (P = 0.003, P = 0.001, respectively). Tumor growth was associated with an increase in β-catenin and c-Myc expression. The growth of xenograft tumors was greater in PPAR-γ ligand-treated mice than in control mice (control vs day 14: P = 0.024, control vs day 28: P = 0.007). The expression of β-catenin and c-Myc protein were also elevated in PPAR-γ-treated mouse tissues. PPAR-γ ligand can promote the growth of APC-mutated HT-29 colon cancer cells in vitro and in vivo. In addition, the tumor promoting effect seems to be associated with an increase in β-catenin and c-Myc expression. We think that well-controlled clinical trials should be conducted to confirm our results and to verify clinical applications.
| Original language | English |
|---|---|
| Pages (from-to) | 283-288 |
| Number of pages | 6 |
| Journal | Investigational New Drugs |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2008 Jun 1 |
Fingerprint
Keywords
- β-Catenin
- APC-mutated
- c-Myc
- PPAR-γ ligand
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
Cite this
PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. / Choi, I. K.; Kim, Yeul Hong; Kim, Jun Suk; Seo, Jae Hong.
In: Investigational New Drugs, Vol. 26, No. 3, 01.06.2008, p. 283-288.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo
AU - Choi, I. K.
AU - Kim, Yeul Hong
AU - Kim, Jun Suk
AU - Seo, Jae Hong
PY - 2008/6/1
Y1 - 2008/6/1
N2 - PPAR-γ has been known to induce suppression, differentiation and reversal of malignant changes in colon cancer in vitro. However, there are several reports that PPAR-γ ligands enhance colon polyp development in APCmin mice in vivo. These contradictory results have not yet been thoroughly explained. To explain the contradictory results, we analyzed the effects of different concentrations of the PPAR-γ agonist, 15-deoxy-D12, 14-prostaglandin (15-d Δ PGJ2) and pioglitazone, on APC gene-mutated colon cancer cell lines (HT-29). We measured cell growth and suppression by cell count and MTT assay and analyzed the expression of β-catenin and c-Myc protein by Western blot. In addition, we inoculated HT-29 cells into APC min mice to compare tumor size. High concentrations (10-100 μM/L 15-d Δ PGJ2 and pioglitazone) of PPAR-γ ligand suppressed growth, while low concentrations (0.01-1 μM/L 15-d Δ PGJ2 and pioglitazone) of PPAR-γ ligand promoted growth. In particular, the effects of 0.1 μM/L 15-d Δ PGJ2 and pioglitazone on cell growth were statistically significant (P = 0.003, P = 0.001, respectively). Tumor growth was associated with an increase in β-catenin and c-Myc expression. The growth of xenograft tumors was greater in PPAR-γ ligand-treated mice than in control mice (control vs day 14: P = 0.024, control vs day 28: P = 0.007). The expression of β-catenin and c-Myc protein were also elevated in PPAR-γ-treated mouse tissues. PPAR-γ ligand can promote the growth of APC-mutated HT-29 colon cancer cells in vitro and in vivo. In addition, the tumor promoting effect seems to be associated with an increase in β-catenin and c-Myc expression. We think that well-controlled clinical trials should be conducted to confirm our results and to verify clinical applications.
AB - PPAR-γ has been known to induce suppression, differentiation and reversal of malignant changes in colon cancer in vitro. However, there are several reports that PPAR-γ ligands enhance colon polyp development in APCmin mice in vivo. These contradictory results have not yet been thoroughly explained. To explain the contradictory results, we analyzed the effects of different concentrations of the PPAR-γ agonist, 15-deoxy-D12, 14-prostaglandin (15-d Δ PGJ2) and pioglitazone, on APC gene-mutated colon cancer cell lines (HT-29). We measured cell growth and suppression by cell count and MTT assay and analyzed the expression of β-catenin and c-Myc protein by Western blot. In addition, we inoculated HT-29 cells into APC min mice to compare tumor size. High concentrations (10-100 μM/L 15-d Δ PGJ2 and pioglitazone) of PPAR-γ ligand suppressed growth, while low concentrations (0.01-1 μM/L 15-d Δ PGJ2 and pioglitazone) of PPAR-γ ligand promoted growth. In particular, the effects of 0.1 μM/L 15-d Δ PGJ2 and pioglitazone on cell growth were statistically significant (P = 0.003, P = 0.001, respectively). Tumor growth was associated with an increase in β-catenin and c-Myc expression. The growth of xenograft tumors was greater in PPAR-γ ligand-treated mice than in control mice (control vs day 14: P = 0.024, control vs day 28: P = 0.007). The expression of β-catenin and c-Myc protein were also elevated in PPAR-γ-treated mouse tissues. PPAR-γ ligand can promote the growth of APC-mutated HT-29 colon cancer cells in vitro and in vivo. In addition, the tumor promoting effect seems to be associated with an increase in β-catenin and c-Myc expression. We think that well-controlled clinical trials should be conducted to confirm our results and to verify clinical applications.
KW - β-Catenin
KW - APC-mutated
KW - c-Myc
KW - PPAR-γ ligand
UR - http://www.scopus.com/inward/record.url?scp=42549146102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42549146102&partnerID=8YFLogxK
U2 - 10.1007/s10637-007-9108-x
DO - 10.1007/s10637-007-9108-x
M3 - Article
C2 - 18161004
AN - SCOPUS:42549146102
VL - 26
SP - 283
EP - 288
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 3
ER -